

Jae-Cheol Jo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/485507/publications.pdf>

Version: 2024-02-01

100
papers

1,440
citations

471509

17
h-index

377865

34
g-index

107
all docs

107
docs citations

107
times ranked

2359
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts. <i>Cancer Research and Treatment</i> , 2023, 55, 325-333.	3.0	2
2	Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen. <i>Blood Research</i> , 2022, 57, 51-58.	1.3	3
3	Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling. <i>PLoS ONE</i> , 2022, 17, e0265958.	2.5	4
4	Clinicopathologic Characteristics Associated with Prognosis in Ocular Extranodal Marginal Zone B Cell Lymphoma. <i>Medicina (Lithuania)</i> , 2022, 58, 818.	2.0	0
5	Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation. <i>Supportive Care in Cancer</i> , 2021, 29, 975-986.	2.2	20
6	Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). <i>Gastric Cancer</i> , 2021, 24, 156-167.	5.3	29
7	Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas. <i>Annals of Hematology</i> , 2021, 100, 189-196.	1.8	2
8	Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2021, 113, 81-91.	1.6	3
9	Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. <i>Annals of Hematology</i> , 2021, 100, 2051-2059.	1.8	6
10	Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation. <i>Clinical Transplantation</i> , 2021, 35, e14199.	1.6	4
11	LIGHT (TNFSF14) enhances osteogenesis of human bone marrow-derived mesenchymal stem cells. <i>PLoS ONE</i> , 2021, 16, e0247368.	2.5	4
12	Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis. <i>Cancer Communications</i> , 2021, 41, 275-278.	9.2	4
13	Pegteograstim prophylaxis for chemotherapy-induced neutropenia and febrile neutropenia: a prospective, observational, postmarketing surveillance study in Korea. <i>Supportive Care in Cancer</i> , 2021, 29, 5383-5390.	2.2	2
14	Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act. <i>BMC Palliative Care</i> , 2021, 20, 63.	1.8	8
15	The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway. <i>Scientific Reports</i> , 2021, 11, 13198.	3.3	5
16	Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 194-204.	1.7	6
17	Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population. <i>Scientific Reports</i> , 2021, 11, 22907.	3.3	3
18	Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT. <i>Blood Cancer Journal</i> , 2021, 11, 190.	6.2	10

#	ARTICLE	IF	CITATIONS
19	Pegfilgrastim Prophylaxis is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. <i>Cancer Research and Treatment</i> , 2021, . .	3.0	4
20	A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2020, 99, 255-264.	1.8	3
21	Poor prognostic impact of high serum ferritin levels in patients with a lower risk of diffuse large B cell lymphoma. <i>International Journal of Hematology</i> , 2020, 111, 559-566.	1.6	10
22	The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study). <i>Annals of Hematology</i> , 2020, 99, 309-319.	1.8	5
23	Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report. <i>Annals of Hematology</i> , 2020, 99, 223-228.	1.8	6
24	Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study. <i>Scientific Reports</i> , 2020, 10, 13359.	3.3	4
25	Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death. <i>BMC Cancer</i> , 2020, 20, 1193.	2.6	8
26	Monosomal karyotype affecting outcomes of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. <i>European Journal of Haematology</i> , 2020, 105, 262-273.	2.2	3
27	Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study. <i>International Journal of Hematology</i> , 2020, 112, 84-95.	1.6	5
28	Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL). <i>Bone Marrow Transplantation</i> , 2020, 55, 1466-1468.	2.4	2
29	CD45dimCD34+CD38~CD133+ cells have the potential as leukemic stem cells in acute myeloid leukemia. <i>BMC Cancer</i> , 2020, 20, 285.	2.6	13
30	Frontline therapy for newly diagnosed patients with multiple myeloma. <i>Blood Research</i> , 2020, 55, S37-S42.	1.3	12
31	Distinct Clinical Features of Plasma Cell Myeloma Patients Exhibiting Dysmorphic Plasma Cells: Association with More Plasma Cells at Diagnosis. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 662-672.	0.6	0
32	Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2051-2059.	2.4	2
33	The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores. <i>International Journal of Hematology</i> , 2019, 110, 438-446.	1.6	7
34	High-grade nodal marginal zone lymphoma with diffuse bone marrow involvement and IgM-type monoclonal paraproteinemia: a case report and review of the literature. <i>Blood Research</i> , 2019, 54, 229-231.	1.3	1
35	Bone marrow metastasis of small cell lung carcinoma with spontaneous tumor lysis syndrome without hepatic metastasis at diagnosis: first case report in Korea and review of literature. <i>Blood Research</i> , 2019, 54, 231-233.	1.3	3
36	Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma. <i>Annals of Hematology</i> , 2019, 98, 2541-2550.	1.8	43

#	ARTICLE	IF	CITATIONS
37	A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial). <i>Leukemia and Lymphoma</i> , 2019, 60, 3251-3257.	1.3	4
38	Radotinib inhibits mitosis entry in acute myeloid leukemia cells via suppression of Aurora kinase A expression. <i>Tumor Biology</i> , 2019, 41, 101042831984861.	1.8	11
39	The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients. <i>International Journal of Cancer</i> , 2019, 145, 2459-2467.	5.1	7
40	Clinical Utility of 18F-Florbetaben PET for Detecting Amyloidosis Associated With Multiple Myeloma. <i>Clinical Nuclear Medicine</i> , 2019, 44, e503-e509.	1.3	10
41	Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. <i>Scientific Reports</i> , 2019, 9, 20302.	3.3	12
42	Chronic Vasitis After Mesh Herniorrhaphy. <i>Clinical Nuclear Medicine</i> , 2019, 44, e104-e106.	1.3	2
43	Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 149-156.	0.4	2
44	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. <i>Annals of Hematology</i> , 2018, 97, 1437-1443.	1.8	16
45	Low-grade follicular lymphoma involvement of the bone marrow with a mixed paratrabeular, diffuse, and massive pattern expressing typical mantle cell lymphoma immunophenotype CD23 ⁺ /FMC7 ⁺ : a case report. <i>Blood Research</i> , 2018, 53, 261.	1.3	0
46	Rhein augments ATRA-induced differentiation of acute promyelocytic leukemia cells. <i>Phytomedicine</i> , 2018, 49, 66-74.	5.3	14
47	Electrophysiologic features of POEMS syndrome compared with MGUS-related neuropathy. <i>Muscle and Nerve</i> , 2017, 56, E73-E77.	2.2	7
48	Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1555-1566.	2.0	21
49	Radotinib induces high cytotoxicity in c-KIT positive acute myeloid leukemia cells. <i>European Journal of Pharmacology</i> , 2017, 804, 52-56.	3.5	10
50	Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. <i>American Journal of Hematology</i> , 2017, 92, 1280-1286.	4.1	34
51	Interim 18F-FDG PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine. <i>Annals of Hematology</i> , 2017, 96, 1509-1515.	1.8	15
52	Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death. <i>Scientific Reports</i> , 2017, 7, 15278.	3.3	54
53	Trend and treatment patterns of aplastic anemia in Korea, pure red cell aplasia and myelodysplastic syndrome in Korea: a nation-wide analysis. <i>International Journal of Hematology</i> , 2017, 106, 500-507.	1.6	2
54	Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type. <i>Annals of Hematology</i> , 2017, 96, 25-31.	1.8	81

#	ARTICLE	IF	CITATIONS
55	Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. <i>Blood Research</i> , 2017, 52, 200.	1.3	9
56	Mass-Forming Extramedullary Hematopoiesis in Multiple Myeloma: ¹⁸ F-FDG PET/CT is useful in Excluding Extramedullary Myeloma Involvement. <i>Tumori</i> , 2016, 102, S116-S118.	1.1	4
57	LIGHT (TNFSF14) Increases the Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells. <i>PLoS ONE</i> , 2016, 11, e0166589.	2.5	17
58	A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60Åyr with resistant acute myeloid leukemia: a comparison with intensive younger patientsâ€™ trial. <i>European Journal of Haematology</i> , 2016, 96, 188-197.	2.2	11
59	Coexistence of follicular lymphoma and an unclassifiable myeloproliferative neoplasm in a treatment-naïve patient: A case report. <i>Oncology Letters</i> , 2016, 11, 1469-1473.	1.8	4
60	The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. <i>Annals of Hematology</i> , 2016, 95, 911-919.	1.8	4
61	Metastatic prostate cancer initially presenting as chylothorax: A case report. <i>Molecular and Clinical Oncology</i> , 2016, 4, 1009-1012.	1.0	1
62	Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors. <i>European Journal of Pharmacology</i> , 2016, 789, 280-290.	3.5	13
63	Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 159-166.	1.1	1
64	Peripheral T cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK). <i>Annals of Hematology</i> , 2016, 95, 619-624.	1.8	4
65	A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 389-400.	10.7	285
66	Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor. <i>Blood</i> , 2016, 128, 3313-3313.	1.4	5
67	Clinical Usefulness of Inflammatory Factors Based Modified International Prognostic Index in Diffuse Large B Cell Lymphoma Treated with Rituximab Combined Chemotherapy. <i>Blood</i> , 2016, 128, 4220-4220.	1.4	4
68	Angioimmunoblastic T-Cell Lymphoma in a Patient with Klinefelter Syndrome. <i>American Journal of Case Reports</i> , 2016, 17, 529-534.	0.8	3
69	LIGHT (TNFSF14) Increases Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells Via LTÎ²R. <i>Blood</i> , 2016, 128, 4546-4546.	1.4	0
70	The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160). <i>Blood</i> , 2016, 128, 4445-4445.	1.4	0
71	A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-Cell Lymphoma (BENCART): A Consortium for Improving Survival of Lymphoma (CISL) Trial. <i>Blood</i> , 2016, 128, 1823-1823.	1.4	0
72	Adjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: A single center experience in Korea. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 282-287.	1.1	17

#	ARTICLE	IF	CITATIONS
73	Radotinib Induces Apoptosis of CD11b+ Cells Differentiated from Acute Myeloid Leukemia Cells. PLoS ONE, 2015, 10, e0129853.	2.5	18
74	Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2015, 21, 1597-1604.	2.0	76
75	Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity. Molecular Cancer Therapeutics, 2015, 14, 2613-2622.	4.1	24
76	Rosmarinic acid potentiates ATRA-induced macrophage differentiation in acute promyelocytic leukemia NB4 cells. European Journal of Pharmacology, 2015, 747, 36-44.	3.5	28
77	Diffuse Large B-Cell Lymphoma with Involvement of the Breast and Testis in a Male Patient. Cancer Research and Treatment, 2015, 47, 539-543.	3.0	3
78	A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. Investigational New Drugs, 2014, 32, 369-376.	2.6	61
79	Clinical significance of the appearance of abnormal protein band in patients with multiple myeloma. Annals of Hematology, 2014, 93, 463-469.	1.8	13
80	Dasatinib Accelerates Valproic Acid-Induced Acute Myeloid Leukemia Cell Death by Regulation of Differentiation Capacity. PLoS ONE, 2014, 9, e98859.	2.5	23
81	A Prospective Randomized Comparison of Cyclophosphamide Versus Fludarabine in Addition of Antithymocyte Globuline for Allogeneic Hematopoietic Cell Transplantation in Patients with Adult Severe Aplastic Anemia; Interim Analysis. Blood, 2014, 124, 3890-3890.	1.4	0
82	Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience. Cancer Chemotherapy and Pharmacology, 2013, 72, 201-207.	2.3	23
83	Serum CA19-9 as a prognostic factor in patients with metastatic gastric cancer. Asia-Pacific Journal of Clinical Oncology, 2013, 9, 324-330.	1.1	28
84	Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer. European Journal of Dermatology, 2013, 23, 77-82.	0.6	10
85	Comparable Allogeneic Hematopoietic Cell Transplantation Outcome Of Haplo-Identical Family Donor With Matched Unrelated/Mismatched Family Donor In Adult Aplastic Anemia. Blood, 2013, 122, 1230-1230.	1.4	0
86	Prognostic Significance Of Systemic Inflammatory Factors In Patients With Diffuse Large B Cell Lymphoma Treated By R-CHOP. Blood, 2013, 122, 1802-1802.	1.4	5
87	Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma. The Korean Journal of Hematology, 2012, 47, 119.	0.7	10
88	Increment of hematopoietic progenitor cell count as an indicator of efficient autologous stem cell harvest in patients with multiple myeloma. Journal of Clinical Apheresis, 2012, 27, 229-234.	1.3	4
89	Clinical features and prognostic model for extranasal NK/T-cell lymphoma. European Journal of Haematology, 2012, 89, 103-110.	2.2	53
90	Clinical Significance of Immunoglobulin Isotype Switching in Patients with Multiple Myeloma. Blood, 2012, 120, 4980-4980.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Prognostic Value of Positron Emission Tomography- Computed Tomography in Patients with Marginal Zone Lymphoma. <i>Blood</i> , 2012, 120, 5084-5084.	1.4	1
92	Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma. <i>Investigational New Drugs</i> , 2011, 29, 175-181.	2.6	3
93	Yttrium-90-Ibritumomab Tiuxetan and BuCyE High-Dose Chemotherapy Compared with BuCyE Alone As Conditioning Regimen in Patients with B-Cell Non-Hodgkin Lymphoma: IPI Matched Case Control Study At a Single Center,. <i>Blood</i> , 2011, 118, 3703-3703.	1.4	0
94	BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. <i>Annals of Hematology</i> , 2008, 87, 43-48.	1.8	75
95	Infarction and Perforation of the Small Intestine due to Tumor Emboli from Disseminated Rectal Cancer. <i>Gut and Liver</i> , 2008, 2, 130-132.	2.9	3
96	Both-sided Intra-atrial Intracardiac Metastases as the Initial Presentation of Testicular Seminoma. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 463-468.	1.3	5
97	Docetaxel Monotherapy as a Second-line Treatment after Failure of Fluoropyrimidine and Platinum in Advanced Gastric Cancer: Experience of 154 Patients with Prognostic Factor Analysis. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 936-941.	1.3	41
98	Multicenter Phase II Trial of 90Y-Ibritumomab Tiuxetan with High-Dose Chemotherapy (Busulfan/Cyclophosphamide/Etoposide) Followed by Autologous Stem Cell Transplantation in Relapsed, Refractoried, or High-Risk B-Cell NHL.. <i>Blood</i> , 2007, 110, 1914-1914.	1.4	1
99	Initial Cytoreductive Treatment with Thalidomide Plus Bolus Vincristine/Doxorubicin and Reduced Dexamethasone (T-bVAd) Followed by Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma.. <i>Blood</i> , 2007, 110, 5094-5094.	1.4	0
100	Clinical outcomes of early-progressed follicular lymphoma in Korea: a multicenter, retrospective analysis. <i>Archives of Medical Science</i> , 0, , .	0.9	0